Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
| Autor: | Jacene, Heather, Crandall, John, Kasamon, Yvette L, Ambinder, Richard F, Piantadosi, Steven, Serena, Donna, Kasecamp, Wayne, Wahl, Richard L |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male [I-131]tositumomab Lymphoma FDG Physiology Clinical Sciences Antibodies Cohort Studies Dose-Response Relationship Young Adult Rare Diseases Hodgkin Clinical Research Monoclonal Humans Cancer Radiation Bexxar [131I]tositumomab Hematology Middle Aged Hodgkin Disease Nuclear Medicine & Medical Imaging Orphan Drug Neoplasm Recurrence Treatment Outcome Local Biomedical Imaging Female Whole-Body Irradiation Hodgkin lymphoma |
| Zdroj: | Molecular imaging and biology, vol 19, iss 3 Jacene, H; Crandall, J; Kasamon, YL; Ambinder, RF; Piantadosi, S; Serena, D; et al.(2017). Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Molecular Imaging and Biology, 19(3), 429-436. doi: 10.1007/s11307-016-1019-9. UCLA: Retrieved from: http://www.escholarship.org/uc/item/3fv9962m |
| DOI: | 10.1007/s11307-016-1019-9. |
| Popis: | PurposeTo determine the maximum tolerated dose (MTD) of [131I]tositumomab in patients with refractory/recurrent Hodgkin lymphoma (HL) and to preliminarily determine if [131I]tositumomab has activity against HL and if positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]DG) performed 6weeks post-therapy predicted 12-week response.ProceduresSeparate dose-finding studies were performed for patients with and without prior transplant. A single therapeutic total body radiation dose (TBD) of [131I]tositumomab was administered. TBD was escalated/de-escalated based on dose-limiting hematologic toxicity (DLT) using a modified continual reassessment method. [18F]DG-PET/CT scans were performed at baseline and 6 and 12weeks post therapy.ResultsTwelve patients (nine classical HL, three lymphocyte-predominant [LP] HL) completed two dosing levels (n=3 each) in the post-transplant (55cGy, 79cGy) and no transplant (75cGy, 87cGy) groups. Hematologic toxicities were common and transient. Twelve weeks after [131I]tositumomab, 10 patients progressed and two with LPHL achieved complete response. [18F]DG-PET/CT at 6weeks post therapy appeared more predictive than CT at 6weeks of a response at 12weeks.ConclusionsTositumomab and [131I]tositumomab was well-tolerated in patients with relapsed/refractory HL. Complete responses in LPHL support a therapeutic effect in this subtype. Early metabolic response assessments by [18F]DG-PET in HL after radioimmunotherapy appear to be more predictive than purely anatomic assessments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|